http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-0313377-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-62
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-34
filingDate 2003-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ce9fa6939b2755aa4ae654daddc766c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_571d790e60f8c52da323e4d6997ae3f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75195ad9bdcd1d64417692f949fb64b2
publicationDate 2005-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber BR-0313377-A
titleOfInvention N-aryl piperidine-substituted biphenylcarnboxamides as apolipoprotein b secretion inhibitors
abstract "Biphenylcarboxamides Replaced by N-Aryl Piperidine as Inhibitors of APOLIPOPROTEIN B Secretion". The present invention relates to N-aryl piperidine substituted biphenylcarboxamide compounds of formula (I), methods for preparing such compounds, pharmaceutical compositions comprising such compounds, and the use of such compounds as a medicament for the treatment of hyperlipidemia, obesity and type II diabetes. The compounds act as apolipoprotein B inhibitors.
priorityDate 2002-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID338
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID54225
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID238055
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID494004
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421039224
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID83254

Total number of triples: 33.